Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Overcoming drug resistance in ALK-rearranged lung cancer.

× No keyword cloud information.

9 in total

1. miR-223/FBW7 axis regulates doxorubicin sensitivity through epithelial mesenchymal transition in non-small cell lung cancer.

Authors: Renyuan Li; Shengjun Wu; Xin Chen; Hongfei Xu; Peng Teng; Weidong Li
Journal: Am J Transl Res Date: 2016-06-15 Impact factor: 4.060

2. Reduction of leukemia cell burden and restoration of normal hematopoiesis at 3 months of crizotinib treatment in RAN-binding protein 2 (RANBP2)-anaplastic lymphoma kinase (ALK) acute myeloid leukemia.

Authors: Y Maesako; A Okumura; K Takeoka; C Kishimori; K Izumi; Y Kamoda; F Iioka; T Akasaka; H Ohno
Journal: Leukemia Date: 2014-05-21 Impact factor: 11.528

3. Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.

Authors: Heloisa Veasey Rodrigues; Danxia Ke; JoAnn Lim; Bettzy Stephen; Jorge Bellido; Filip Janku; Ralph Zinner; Apostolia Tsimberidou; David Hong; Sarina Piha-Paul; Siqing Fu; Aung Naing; Vivek Subbiah; Daniel Karp; Gerald Falchook; Razelle Kurzrock; Jennifer Wheler
Journal: Invest New Drugs Date: 2015-04-24 Impact factor: 3.850

Review 4. Ceritinib: first global approval.

Authors: Sohita Dhillon; Madeleine Clark
Journal: Drugs Date: 2014-07 Impact factor: 9.546

Review 5. Adeno-associated virus-mediated cancer gene therapy: current status.

Authors: Jingfeng Luo; Yuxuan Luo; Jihong Sun; Yurong Zhou; Yajing Zhang; Xiaoming Yang
Journal: Cancer Lett Date: 2014-11-10 Impact factor: 8.679

6. Computationally unraveling how ceritinib overcomes drug-resistance mutations in ALK-rearranged lung cancer.

Authors: Zhong Ni; Tian-Cheng Zhang
Journal: J Mol Model Date: 2015-06-18 Impact factor: 1.810

7. Early and late effects of pharmacological ALK inhibition on the neuroblastoma transcriptome.

Authors: Shana Claeys; Geertrui Denecker; Robrecht Cannoodt; Candy Kumps; Kaat Durinck; Frank Speleman; Katleen De Preter
Journal: Oncotarget Date: 2017-11-06

8. N-Acetyltransferase 10 Enhances Doxorubicin Resistance in Human Hepatocellular Carcinoma Cell Lines by Promoting the Epithelial-to-Mesenchymal Transition.

Authors: Xiuming Zhang; Jiang Chen; Shi Jiang; Shilin He; Yanfeng Bai; Linghua Zhu; Rui Ma; Xiao Liang
Journal: Oxid Med Cell Longev Date: 2019-07-01 Impact factor: 6.543

9. MicroRNA-9 enhances sensitivity to cetuximab in epithelial phenotype hepatocellular carcinoma cells through regulation of the eukaryotic translation initiation factor 5A-2.

Authors: Fei Xue; Yuntian Liang; Zhenrong Li; Yanhui Liu; Hongwei Zhang; Yu Wen; Lei Yan; Qiang Tang; Erhui Xiao; Dongyi Zhang
Journal: Oncol Lett Date: 2017-11-14 Impact factor: 2.967

9 in total